Bjørn Østenstad

  • Consultant Dr. med.
  • +47 22 93 49 11, 922 18 077
 

Author network for Bjørn Østenstad by COREMINE medical


Publications 2018

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E (2018)
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
J Clin Oncol, 36 (33), 3315-+
DOI 10.1200/JCO.18.00262, PubMed 30285560

Publications 2017

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Publications 2016

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Publications 2015

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C, Nordic Lymphoma Group (NLG) (2015)
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Leuk Lymphoma, 56 (9), 2598-607
DOI 10.3109/10428194.2015.1014363, PubMed 25686644

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE (2015)
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Mol Oncol, 9 (8), 1553-64
DOI 10.1016/j.molonc.2015.04.008, PubMed 26004085

Publications 2014

Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM (2014)
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
Haematologica, 100 (4), 534-40
DOI 10.3324/haematol.2014.108472, PubMed 25480497

Publications 2013

Iversen PO, Negaard H, Østenstad B, Sandset PM, Kolset SO (2013)
Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma
Leuk Lymphoma, 56 (8), 2479-81
DOI 10.3109/10428194.2013.803227, PubMed 23656198

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2013)
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Leuk Lymphoma, 55 (2), 288-95
DOI 10.3109/10428194.2013.802778, PubMed 23662992

Publications 2012

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012)
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
J Clin Oncol, 30 (25), 3093-9
DOI 10.1200/JCO.2011.40.2719, PubMed 22851556

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2012)
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Ann Oncol, 24 (5), 1385-92
DOI 10.1093/annonc/mds621, PubMed 23247661

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE (2012)
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Breast Cancer Res, 14 (2), R47
DOI 10.1186/bcr3147, PubMed 22420423

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E (2012)
Entourage: the immune microenvironment following follicular lymphoma
Blood Cancer J, 2 (1), e52
DOI 10.1038/bcj.2011.53, PubMed 22829236

Publications 2011

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE (2011)
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel
PLoS One, 6 (4), e19249
DOI 10.1371/journal.pone.0019249, PubMed 21556366

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H (2011)
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
Br J Haematol, 152 (5), 600-10
DOI 10.1111/j.1365-2141.2010.08519.x, PubMed 21241276

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO (2011)
Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias
Leuk Lymphoma, 52 (6), 1157-9
DOI 10.3109/10428194.2011.563886, PubMed 21463121

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E (2011)
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab
Clin Cancer Res, 17 (12), 4136-44
DOI 10.1158/1078-0432.CCR-11-0264, PubMed 21518780

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114

Publications 2009

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO (2009)
Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
Leuk Lymphoma, 50 (6), 998-1004
DOI 10.1080/10428190902889270, PubMed 19373600

Publications 2008

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O (2008)
Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells
Transfusion, 49 (2), 354-61
DOI 10.1111/j.1537-2995.2008.01949.x, PubMed 18980622

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE (2008)
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer
PLoS One, 3 (8), e3062
DOI 10.1371/journal.pone.0003062, PubMed 18725978

Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C, Nordic Lymphoma Group (2008)
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
Leuk Lymphoma, 49 (1), 102-12
DOI 10.1080/10428190701704647, PubMed 18203019

Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO (2008)
Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Leukemia, 23 (1), 162-9
DOI 10.1038/leu.2008.255, PubMed 18800145

Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM (2008)
Increased acquired activated protein C resistance in unselected patients with hematological malignancies
J Thromb Haemost, 6 (9), 1482-7
DOI 10.1111/j.1538-7836.2008.03060.x, PubMed 18573186

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506

Publications 2006

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM (2006)
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
DOI 10.1200/JCO.2006.06.4345, PubMed 16763285

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE (2006)
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Clin Cancer Res, 12 (20 Pt 1), 6000-4
DOI 10.1158/1078-0432.CCR-05-2822, PubMed 17062672

Publications 2005

Negaard H, Dahm A, Sandset PM, Iversen PO, Ostenstad B (2005)
Angiogenesis and hemostasis in hematological neoplasias
Curr. Drug Targets, 6 (6), 681-699

Negaard H, Dahm A, Sandset PM, Iversen PO, Østenstad B (2005)
Angiogenesis and hemostasis in hematological neoplasias
Curr Drug Targets, 6 (6), 683-99
PubMed 16178801

Publications 2004

Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C (2004)
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
Br J Cancer, 90 (12), 2344-8
DOI 10.1038/sj.bjc.6601881, PubMed 15150568

Cekaite L, Haug O, Myklebost O, Aldrin M, Østenstad B, Holden M, Frigessi A, Hovig E, Sioud M (2004)
Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method
Proteomics, 4 (9), 2572-82
DOI 10.1002/pmic.200300768, PubMed 15352232

Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I (2004)
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer
Acta Oncol, 43 (2), 186-9
DOI 10.1080/02841860310023165, PubMed 15163168

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K (2004)
Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer
Acta Oncol, 43 (1), 11-4
DOI 10.1080/02841860310017748, PubMed 15068314

Publications 2003

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM (2003)
Epidermal growth factor receptor inhibition induces trichomegaly
Acta Oncol, 42 (4), 345-6
DOI 10.1080/02841860310006038, PubMed 12899508

Publications 2002

Luoma ML, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström P, Bengtsson NO, Hultborn R, Ostenstaad B, Mjaaland I, Valvere V, Wist E, Baldursson G, Ahigren J, Blomqvist C (2002)
Physical performance, toxicity, and quality of life as assessed by the physician and the patient
Acta Oncol, 41 (1), 44-9
DOI 10.1080/028418602317314055, PubMed 11990517

Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstad B, Wist E, Valvere V, Bergh J, Skiold-Petterson D, Saksela E, Blomqvist C (2002)
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Eur. J. Cancer, 38 (4), PII S0959-8049(01)00403-8-542

Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C (2002)
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Eur J Cancer, 38 (4), 535-42
PubMed 11872346

Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C (2002)
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
Br J Cancer, 86 (12), 1905-8
DOI 10.1038/sj.bjc.6600325, PubMed 12085184

Publications 2001

Hakamies-Blomqvist L, Luoma ML, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C (2001)
Timing of quality of life (QoL) assessments as a source of error in oncological trials
J Adv Nurs, 35 (5), 709-16
DOI 10.1046/j.1365-2648.2001.01903.x, PubMed 11529973

Hansen MH, Ostenstad B, Sioud M (2001)
Antigen-specific IgG antibodies in stage IV long-time survival breast cancer patients
Mol Med, 7 (4), 230-9
DOI 10.1007/BF03401842, PubMed 11471567

Hansen MH, Ostenstad B, Sioud M (2001)
Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumour
Int J Oncol, 19 (6), 1303-9
PubMed 11713604

Publications 2000

Hakamies-Blomqvist L, Luoma M, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P, Blomqvist C (2000)
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
Eur J Cancer, 36 (11), 1411-7
DOI 10.1016/S0959-8049(00)00126-X, PubMed 10899655

Publications 1999

Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J (1999)
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group
Eur J Cancer, 35 (8), 1194-201
DOI 10.1016/S0959-8049(99)00122-7, PubMed 10615229

Publications 1997

Ostenstad B, Giliani S, Mellbye OJ, Nilsen BR, Abrahamsen T (1997)
A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency
Clin Exp Immunol, 107 (2), 230-4
DOI 10.1111/j.1365-2249.1997.284-ce1174.x, PubMed 9030857

Publications 1995

Ostenstad B, Dybwad A, Lea T, Førre O, Vinje O, Sioud M (1995)
Evidence for monoclonal expansion of synovial T cells bearing V alpha 2.1/V beta 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens
Immunology, 86 (2), 168-75
PubMed 7490114

Ostenstad B, Sioud M, Schlichting E, Lea T, Harboe M (1995)
Freshly isolated tumour-infiltrating T-lymphocytes have a high cytotoxic potential, as measured by their ability to induce apoptosis in the target cell
Scand J Immunol, 41 (1), 42-8
DOI 10.1111/j.1365-3083.1995.tb03531.x, PubMed 7824887

Publications 1994

Ostenstad B, Harboe M, Lea T (1994)
Differential effects of cyclic adenosine 3',5'-monophosphate on T cell cytotoxicity
Eur J Immunol, 24 (9), 2150-4
DOI 10.1002/eji.1830240932, PubMed 8088333

Ostenstad B, Lea T, Schlichting E, Harboe M (1994)
Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area
Gut, 35 (3), 382-7
DOI 10.1136/gut.35.3.382, PubMed 8150352

Ostenstad B, Sioud M, Lea T, Schlichting E, Harboe M (1994)
Limited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours
Br J Cancer, 69 (6), 1078-82
DOI 10.1038/bjc.1994.211, PubMed 8198973

Publications 1992

Ostenstad B (1992)
Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer
Acta Oncol, 31 (4), 413-5
DOI 10.3109/02841869209088281, PubMed 1632975

Ostenstad B, Andersen OK (1992)
Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia
Acta Oncol, 31 (8), 861-4
DOI 10.3109/02841869209089719, PubMed 1290634

Publications 1990

Tangen JM, Abrahamsen AF, Ostenstad B, Bergheim J (1990)
Interleukin-2 receptor levels in non-Hodgkin's lymphoma. Correlation to histological degree of malignancy and presence of constitutional symptoms
Acta Oncol, 29 (5), 581-3
DOI 10.3109/02841869009090055, PubMed 2206570

Page visits: 139